Pulmatrix is a clinical stage biotechnology company developing a new class of inhaled therapies that harness the body’s natural host defenses and immune response in the airway to safely prevent and treat respiratory infections, reduce inflammation, and prevent acute exacerbations in patients with chronic inflammatory airway disease.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 08/01/11 | Series B | 14M | Unknown |
People
News
Life sciences briefing: Tuesday, Jan. 22, 2007
January 22, 2008 2:17 pm
TODAY’S HEADLINES: Teva acquires protein-therapeutic maker CoGenesys for $400M (release) ViewRay takes in $25M for MRI radiation-therapy guidance (release) NovaMed,… Continue reading ⟩